Dosing
Mounjaro dosage chart: a guide to the label
Mounjaro contains tirzepatide and is labeled for type 2 diabetes. This chart covers adult dosing; pediatric dosing has a different maximum and needs its own clinician-led plan.
How to read a dosage chart
A titration chart describes a labeled schedule, not an instruction to change your own treatment. Starter doses help introduce the medicine; the prescriber selects a maintenance dose according to the indication, response, and tolerability. Calendar weeks do not override side effects or individualized instructions.
Milligrams measure the medicine dose. Milliliters measure liquid volume, and syringe units measure markings on a particular syringe. They are not interchangeable. Never use a brand-name chart to convert a compounded vial into syringe units: concentrations differ, and the pharmacist must provide product-specific instructions.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Labeled schedule
The August 2026 label includes use in patients aged 10 years and older, with a pediatric maximum of 10 mg weekly. An adult chart should not be applied to a child. Mounjaro's diabetes indication is separate from Zepbound's weight-management and sleep-apnea indications, even though both contain tirzepatide.
| Stage or indication | Dose | Meaning |
|---|---|---|
| First 4 weeks | 2.5 mg once weekly | Starting dose; not intended for glycemic control |
| After 4 weeks | 5 mg once weekly | First treatment dose |
| If more glycemic control is needed | Increase by 2.5 mg after at least 4 weeks on the current dose | Adult maximum 15 mg weekly |
Sources: Mounjaro prescribing information
Missed doses and other instructions
The label allows a missed dose within 4 days (96 hours). After that window, skip it and return to the scheduled day. A change in weekly dosing day requires at least 3 days (72 hours) between doses. Contact your prescriber after a prolonged interruption rather than assuming the previous dose remains appropriate.
The device you receive matters. Single-dose pens, multidose pens, prefilled syringes, and vials do not use one universal injection technique. Review the Instructions for Use supplied with your product, and request training when a pharmacy changes the presentation.
Sources: Mounjaro prescribing information
Safety before any dose change
These medicines have boxed warnings about thyroid C-cell tumors observed in rodents; whether the same risk occurs in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. This is different from saying that every thyroid condition prevents treatment.
Review severe stomach problems, previous pancreatitis, gallbladder disease, kidney problems, diabetes-related eye disease, pregnancy plans, and all medicines with your prescriber. Insulin or sulfonylureas can increase the risk of low blood sugar when combined with these treatments. Vomiting and diarrhea can cause dehydration and kidney injury.
Severe persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction require prompt medical assessment. Do not increase a dose to overcome slow weight loss or copy another person's prescription. Tell the anesthesia team about treatment before procedures because delayed gastric emptying can affect aspiration risk.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information
What determines the next dose?
The adult chart describes the permitted sequence, rather than a deadline for reaching 15 mg. After the initial 2.5 mg step, the label ties further increases to a need for additional glycemic control. That makes glucose response, tolerability, and the rest of the diabetes regimen more relevant than a desire to climb the chart quickly. Four weeks is a minimum interval for an increase, not proof that every patient should increase at that point.
A useful follow-up records the current dose, how long it has been taken, glucose measurements requested by the clinician, gastrointestinal symptoms, and any change in other diabetes medicines. If insulin or a sulfonylurea is also prescribed, the clinician may need to reduce its dose to address hypoglycemia risk. Do not make that adjustment yourself or assume that less appetite means insulin is no longer necessary.
Sources: Mounjaro prescribing information
Adult, pediatric, and weight-management decisions
The same medicine name can appear in different clinical conversations. Mounjaro's current label covers type 2 diabetes from age 10, but its pediatric maximum is 10 mg weekly rather than the adult maximum of 15 mg. A chart copied from an adult weight-loss discussion therefore omits a material limit. The label also describes cardiovascular risk reduction in a specified adult diabetes population; that does not turn an adult chart into a universal prevention plan.
For someone seeking treatment for obesity without diabetes, the clinician should explain why Mounjaro rather than the separately labeled Zepbound is being considered. Shared tirzepatide does not make the prescribing indication, insurance documentation, or device instructions interchangeable. If a switch is proposed, request a new plan naming the product, starting or continuing dose, first administration date, and follow-up.
Sources: Mounjaro prescribing information · Zepbound prescribing information
An example of a useful dose conversation
Suppose an adult has completed four weeks at 5 mg, has improving glucose readings, and is struggling to drink enough because of nausea. The chart permits higher steps when additional control is needed; it does not tell that person to increase regardless of symptoms. The next conversation should review the actual benefit, hydration, adverse effects, and other medicines before changing the prescription.
Bring the box or a photograph of its label to resolve any uncertainty about strength and presentation. A different pen, vial, or pharmacy can introduce new handling instructions even when the prescribed milligrams are familiar. Also disclose planned procedures and oral contraception: changing injection time does not remove tirzepatide's absorption precaution, which calls for a non-oral contraceptive method or added barrier protection for four weeks after initiation and each dose increase.
Sources: Mounjaro prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.